Eton Pharmaceutcials, Inc. Common Stock
ETONStock
$37.19+166.81%52W
Market Cap$1.01B
P/E—
Div yield—
Beta0.90
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)123.73%
Price vs S&P 500 (4W)18.41%
VGM Score64.92
Market Capitalization$1.01B
Earnings Surprise History
Q1 260.05est. 0.09
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ETONEton Pharmaceutcials, Inc. Common Stock | D | A | A | $37.19 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Eton Pharmaceuticals is a specialty pharmaceutical company focused on rare diseases with significant unmet patient needs. The company markets four FDA-approved products addressing adrenocortical insufficiency, hyperammonemia, homocystinuria, and hereditary tyrosinemia type 1. Eton is advancing three late-stage product candidates, including an innovative hydrocortisone autoinjector, to expand its rare disease portfolio.